1.
Hematology, Oncology and Stem Cell Therapy. 2014; 7 (4): 162-164
em Inglês
| IMEMR
| ID: emr-153851
RESUMO
Bendamustine is an alkylating agent approved for the treatment of chronic lymphocytic leukemia [CLL] and B-cell non-Hodgkin lymphoma. There are scant reports on bendamustine-induced immune hemolytic anemia occurring mainly in CLL patients. We report a case of immune hemolytic anemia that developed after exposure to bendamustine in a 70-year-old female with CLL who was previously exposed to fludarabine. Previous exposure to fludarabine is a common finding in the majority of reported cases of bendamustine drug-induced immune hemolytic anemia [DIIHA], including our case. Bendamustine should be suspected as the cause of any hemolytic anemia that develops while on this drug, especially in CLL patients treated previously with fludarabine
Assuntos
Humanos , Feminino , Leucemia Linfocítica Crônica de Células B/complicações , Compostos de Mostarda Nitrogenada/efeitos adversos , Anemia Hemolítica , Anemia Hemolítica Autoimune/induzido quimicamente , Doença Crônica
2.
Artigo
em Inglês
| IMSEAR
| ID: sea-18317